 The Atlantic | Why Chemotherapy That Costs $70000 in the US Costs $2500 in India The Atlantic Rejecting the Gleevec patent application is not the only step that the Indian government has taken to circumvent patents on cancer drugs. Last year, India issued a compulsory license on Nexavar, a late-stage kidney and liver cancer treatment, enabling ... Judgment of Novartis Glivec: Taj Pharma and Indian healthcare companies ... |
